Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
42 , D1001D1006 (2014)
Hanmi Pharmaceutical is accelerating its global expansion around efpeglenatide, Koreas first independently developed GLP-1class treatment for obesity and metabolic diseases
FDA-approved GLP-1 receptor agonists include: - Semaglutide (Rybelsus, Ozempic, Wegovy) - Exenatide (Bydureon BCise, Byetta) - Lixisenatide (Adlyxin) - Lixisenatide/insulin glargine (Soliqua) - Liraglutide (Saxenda, Victoza) - Liraglutide/insulin degludec (Xultophy) - Dulaglutide (Trulicity) - Tirzepatide (Mounjaro) For example, Ozempic (semaglutide) is approved for type 2 diabetes, while Wegovy (also semaglutide) is approved for obesity and overweight conditions with related health concerns
Peak Wellness moves to #1: no membership fee, no price increase when your dose goes up, no hidden fees, publicly listed compounding pharmacies (all with zero disciplinary actions), and, as of May 2026, FedEx next-day air shipping
